Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services

Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including to assist in identifying and evaluating targeted M&A opportunities.

“We are incredibly pleased to launch this relationship with Maxim,” stated Frank Adell, CEO of Cognos.

CEO Frank Adell

“We believe Maxim can assist us in pursuing strategic growth and in building long-term value for our shareholders.”

“Our goal is that this will further enable us to focus on our product, the SINNAIS™, a standalone, implantable smart pump. This closed-loop MRI-compatible medical device is designed to deliver therapeutic drugs locally and metronomically to the desired area. Specifically, our focus is on delivering drugs into the neuro region. SINNAIS™ has full wireless communication capability and compatibility with the cloud,” added Adell.

Cognos looks forward to keeping its shareholders apprised of its progress as it moves into this next phase in the Company’s growth trajectory and corporate development plan.

Maxim Group LLC is a full-service investment banking, securities, and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research, and prime brokerage services to a diverse range of corporate clients, institutional investors, and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB) and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc.